Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Virus-infected cells presenting BK virus (BKV) antigens are host cells, primarily renal epithelial cells, that have been infected by the human polyomavirus known as BK virus. These infected cells express and present viral proteins (antigens) on their surface, which can be recognized by the immune system—particularly T lymphocytes. The presence of these antigens is central to both the pathogenesis of BKV-associated diseases and to potential immunotherapeutic targeting. Key viral antigens include Large T antigen, small t antigen, VP1/VP2/VP3 capsid proteins, and agnoprotein. The presentation of these antigens allows recognition by cytotoxic CD8+ T lymphocytes, and evidence suggests CD4+ T cell responses play a direct role in controlling infection. Therapeutically, strategies include boosting anti-BK immunity or directly targeting key viral proteins.
Immune recognition and killing of infected cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Virus-Infected Cells Presenting BK Virus Antigens.